These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

485 related items for PubMed ID: 26991962

  • 41. Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
    Zelniker TA, Ardissino M, Andreotti F, O'Donoghue ML, Yin O, Park JG, Murphy SA, Ruff CT, Lanz HJ, Antman EM, Braunwald E, Giugliano RP, Merlini PA.
    Circulation; 2021 Feb 16; 143(7):673-684. PubMed ID: 33587659
    [Abstract] [Full Text] [Related]

  • 42. Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives.
    Blann AD, Boriani G, Lip GY.
    Europace; 2016 Oct 16; 18(10):1507-1513. PubMed ID: 27876695
    [Abstract] [Full Text] [Related]

  • 43. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.
    Salazar DE, Mendell J, Kastrissios H, Green M, Carrothers TJ, Song S, Patel I, Bocanegra TS, Antman EM, Giugliano RP, Kunitada S, Dornseif B, Shi M, Tachibana M, Zhou S, Rohatagi S.
    Thromb Haemost; 2012 May 16; 107(5):925-36. PubMed ID: 22398655
    [Abstract] [Full Text] [Related]

  • 44. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
    Eisen A, Giugliano RP, Ruff CT, Nordio F, Gogia HS, Awasty VR, Henderson DA, Mercuri MF, Rutman H, Antman EM, Braunwald E.
    Am Heart J; 2016 Feb 16; 172():144-51. PubMed ID: 26856226
    [Abstract] [Full Text] [Related]

  • 45. Edoxaban: Review of pharmacology and key phase I to III clinical trials.
    Plitt A, Giugliano RP.
    J Cardiovasc Pharmacol Ther; 2014 Sep 16; 19(5):409-16. PubMed ID: 24607764
    [Abstract] [Full Text] [Related]

  • 46. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial.
    Verhamme P, Wells PS, Segers A, Ageno W, Brekelmans MP, Cohen AT, Meyer G, Grosso MA, Raskob G, Weitz JI, Zhang G, Buller H.
    Thromb Haemost; 2016 Sep 27; 116(4):747-53. PubMed ID: 27440518
    [Abstract] [Full Text] [Related]

  • 47. The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    Minguet J, Sims HM, Smith KH, Bramlage P.
    Expert Rev Clin Pharmacol; 2017 Jan 27; 10(1):5-15. PubMed ID: 27817212
    [Abstract] [Full Text] [Related]

  • 48. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
    Van Mieghem NM, Unverdorben M, Hengstenberg C, Möllmann H, Mehran R, López-Otero D, Nombela-Franco L, Moreno R, Nordbeck P, Thiele H, Lang I, Zamorano JL, Shawl F, Yamamoto M, Watanabe Y, Hayashida K, Hambrecht R, Meincke F, Vranckx P, Jin J, Boersma E, Rodés-Cabau J, Ohlmann P, Capranzano P, Kim HS, Pilgrim T, Anderson R, Baber U, Duggal A, Laeis P, Lanz H, Chen C, Valgimigli M, Veltkamp R, Saito S, Dangas GD, ENVISAGE-TAVI AF Investigators.
    N Engl J Med; 2021 Dec 02; 385(23):2150-2160. PubMed ID: 34449183
    [Abstract] [Full Text] [Related]

  • 49. Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study.
    Medina A, Raskob G, Ageno W, Cohen AT, Brekelmans MPA, Chen CZ, Grosso MA, Mercuri MF, Segers A, Verhamme P, Vanassche T, Wells PS, Lin M, Winters SM, Weitz JI, Büller HR.
    Thromb Haemost; 2017 Dec 02; 117(12):2406-2414. PubMed ID: 29212128
    [Abstract] [Full Text] [Related]

  • 50. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Mega JL, Walker JR, Ruff CT, Vandell AG, Nordio F, Deenadayalu N, Murphy SA, Lee J, Mercuri MF, Giugliano RP, Antman EM, Braunwald E, Sabatine MS.
    Lancet; 2015 Jun 06; 385(9984):2280-7. PubMed ID: 25769357
    [Abstract] [Full Text] [Related]

  • 51. Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial.
    Boriani G, Ruff CT, Kuder JF, Shi M, Lanz HJ, Antman EM, Braunwald E, Giugliano RP.
    Thromb Haemost; 2021 Feb 06; 121(2):140-149. PubMed ID: 32920808
    [Abstract] [Full Text] [Related]

  • 52. Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review.
    Cuker A, Husseinzadeh H.
    J Thromb Thrombolysis; 2015 Apr 06; 39(3):288-94. PubMed ID: 25669624
    [Abstract] [Full Text] [Related]

  • 53. Edoxaban: pharmacological principles, preclinical and early-phase clinical testing.
    Partida RA, Giugliano RP.
    Future Cardiol; 2011 Jul 06; 7(4):459-70. PubMed ID: 21797743
    [Abstract] [Full Text] [Related]

  • 54. Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study.
    de Groot JR, Ruff CT, Murphy SA, Hamershock RA, Vehmeijer JT, Oude Ophuis AJM, Grip L, Lanz H, Mercuri MF, Antman EM, Giugliano RP.
    Am Heart J; 2021 May 06; 235():132-139. PubMed ID: 33493453
    [Abstract] [Full Text] [Related]

  • 55. Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure.
    Aspromonte N, Colivicchi F.
    Expert Opin Drug Metab Toxicol; 2017 Jan 06; 13(1):113-122. PubMed ID: 27819149
    [Abstract] [Full Text] [Related]

  • 56. The safety of edoxaban for treating atrial fibrillation.
    Hammwöhner M, Goette A.
    Expert Opin Drug Saf; 2017 Nov 06; 16(11):1295-1303. PubMed ID: 28862063
    [Abstract] [Full Text] [Related]

  • 57. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
    De Caterina R, Renda G, Carnicelli AP, Nordio F, Trevisan M, Mercuri MF, Ruff CT, Antman EM, Braunwald E, Giugliano RP.
    J Am Coll Cardiol; 2017 Mar 21; 69(11):1372-1382. PubMed ID: 28302288
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
    Link MS, Giugliano RP, Ruff CT, Scirica BM, Huikuri H, Oto A, Crompton AE, Murphy SA, Lanz H, Mercuri MF, Antman EM, Braunwald E, ENGAGE AF-TIMI 48 Investigators.
    Circ Arrhythm Electrophysiol; 2017 Jan 21; 10(1):. PubMed ID: 28077507
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.